Hydrochloric Acid → 4-cyclopropyl-2-(5-(5-(isopropylamino)-1,3,4-oxadiazol-2-yl)-1-tosyl-1H-indol-3-yl)pyrimidine-5-carboxylic acid
反応式
[CH:1]1([C:4]2[C:9]([C:10]([O:12]C)=[O:11])=[CH:8][N:7]=[C:6]([C:14]3[C:22]4[C:17](=[CH:18][CH:19]=[C:20]([C:23]5[O:24][C:25]([NH:28][CH:29]([CH3:31])[CH3:30])=[N:26][N:27]=5)[CH:21]=4)[N:16]([S:32]([C:35]4[CH:41]=[CH:40][C:38]([CH3:39])=[CH:37][CH:36]=4)(=[O:34])=[O:33])[CH:15]=3)[N:5]=2)[CH2:3][CH2:2]1.C1COCC1.O.[OH-].[Li+].Cl>O>[CH:1]1([C:4]2[C:9]([C:10]([OH:12])=[O:11])=[CH:8][N:7]=[C:6]([C:14]3[C:22]4[C:17](=[CH:18][CH:19]=[C:20]([C:23]5[O:24][C:25]([NH:28][CH:29]([CH3:31])[CH3:30])=[N:26][N:27]=5)[CH:21]=4)[N:16]([S:32]([C:35]4[CH:41]=[CH:40][C:38]([CH3:39])=[CH:37][CH:36]=4)(=[O:33])=[O:34])[CH:15]=3)[N:5]=2)[CH2:3][CH2:2]1参加物
6
実験手順
Methyl 4-cyclopropyl-2-(5-(5-(isopropylamino)-1,3,4-oxadiazol-2-yl)-1-tosyl-1H-indol-3-yl)pyrimidine-5-carboxylate (110 mg, 0.192 mmol) was treated with THF (2 mL), water (1.0 mL) and lithium hydroxide monohydrate (20 mg, 0.48 mmol) and stirred at RT for 1.5 h. The reaction mixture was treated with a 5 N HCl (0.5 mL) and concentrated on the rotovap. It was then dried further by azeotroping with toluene and drying under high vacuum at 50° C. for 3 h. MS (ESI, pos. ion) m/z: 559.0 (M+H)+. It was then used in the subsequent step with further purification.
後処理
- concentrationconcentrated on the rotovap
- customIt was then dried further
- customby azeotroping with toluene
- customdrying under high vacuum at 50° C. for 3 h
- customIt was then used in the subsequent step with further purification
出典と根拠
- ORDレコード
- ord-77b2e696054c4d599e950d05d5de1023
- 出典データセット
- uspto-grants-2016_04
- 特許番号
- US09321756B2
反応ノート
読み込み中…